Eurand Appoints Dr. Ruth Thieroff-Ekerdt as Chief Medical Officer

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

PHILADELPHIA, Nov. 20, 2008 (GLOBE NEWSWIRE) -- Eurand N.V.
(Nasdaq:EURX), a specialty pharmaceutical company that develops
enhanced pharmaceutical and biopharmaceutical products based on its
proprietary drug formulation technologies, today announced the
appointment of Ruth Thieroff-Ekerdt, M.D., to the newly created
position of Chief Medical Officer of Eurand Pharmaceuticals, Inc.,
effective December 1, 2008. She will be based in the Company's
Yardley, Pa., office.

Dr. Thieroff-Ekerdt will have full responsibility for managing
Eurand's clinical research and development, medical and regulatory
affairs, and drug safety and surveillance activities.

"We are delighted to welcome Ruth to the Eurand team," said Gearoid
Faherty, Chairman and Chief Executive Officer. "We look forward to
benefiting from her expertise, leadership skills and wide range of
experience in all phases of drug development."

Before joining Eurand, Dr. Thieroff-Ekerdt was Vice President, Global
Clinical and Medical Affairs, for Bayer Consumer Care, with
responsibility for clinical development, clinical operations, medical
affairs and pharmacovigilance for consumer care products worldwide.
Her experience also includes positions of increasing scope and
responsibility at the Berlex Inc. division of Schering AG. She began
her career at Schering in research.

Dr. Thieroff-Ekerdt received her M.D. from the Free University of
Berlin, Germany.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four products approved by the FDA since
2001 and has a pipeline of product candidates in development for
itself and its collaboration partners. Eurand's technology platforms
include bioavailability enhancement of poorly soluble drugs,
customized release, taste-masking/fast-dissolving formulations and
drug conjugation.
Eurand is a global company with facilities in the U.S. and Europe.
For more information, visit Eurand's website at www.eurand.com.

Forward-Looking Statement

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to the future and status of our NDA filing
for EUR-1008, enrollment and future plans for our clinical trials,
progress of and reports of results from clinical studies, clinical
development plans and product development activities. The words
"potentially," "anticipates," "could," "calls for" and similar
expressions also identify forward-looking statements. These
statements are based upon management's current expectations and are
subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from those
expressed or implied in such statements. Factors that could affect
actual results include risks associated with the possibility that the
FDA does not approve our NDA relating to EUR-1008 or continues to
delay approval; the outcome of any discussions with the FDA; and
unexpected delays or additional requirements in preparation of
materials for submission to the FDA as a part of our NDA filing,
including those relating to Eurand's raw material supplier.
Forward-looking statements contained in this press release are made
as of this date, and we undertake no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events or otherwise. Actual events could differ
materially from those anticipated in the forward-looking statements.

CONTACT: Eurand N.V.
Bill Newbould, Vice President, Investor Relations
+1 267-759-9335
bill.newbould@eurand.com

The Ruth Group
Nick Laudico
+1 646-536-7030
nlaudico@theruthgroup.com
Sara Ephraim
+1 646-536-7002
sephraim@theruthgroup.com

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

WKN: A0MSPK; ISIN:
NL0000886448;
;
Copyright © Hugin AS 2008. All rights reserved.